Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia

International Journal of Hematology

Volumn 99, Issue 5, 2014, Pages 597-602

  Morimoto, Yoshihito ^a   Yoshida, Nao ^a   Kawashima, Nozomu ^a   Matsumoto, Kimikazu ^a   Kato, Koji ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Children; Immune thrombocytopenia; Intravenous immunoglobulin; Prognostic factor; Thrombocytopenia free survival

Indexed keywords

IMMUNOGLOBULIN G; SULFONATED IMMUNOGLOBULIN; IMMUNOGLOBULIN;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HELICOBACTER INFECTION; HUMAN; IMMUNE THROMBOCYTOPENIA; INFANT; JAPANESE (PEOPLE); LEUKOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; RISK FACTOR; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; MORTALITY; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; LEUKOCYTE COUNT; MALE; PLATELET COUNT; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84901586621     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1551-9     Document Type: Article

References (24)

1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. Br J Haematol. 2006;133:364-74.
2. Kalpatthi R, Bussel JB. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr. 2008;20:8-16.
3. Buchanan GR, Adix L. Outcome measures and treatment end points other than platelet count in childhood idiopathic thrombocytopenic purpura. Semin Thromb Hemost. 2001;27:277-85. (Pubitemid 32550169)
4. Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149:855-64.
5. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-93.
6. Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicenter study on 33 patients. Br J Haematol. 2011;155:498-508.
7. Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013;160:538-46.
8. Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98:24-33.
9. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40. (Pubitemid 26230668)
10. Fujisawa K, Iyori H, Ohkawa H, Konishi S, Bessho F, Shirahata A, et al. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol. 2000;72:376-83.
11. Fujisawa K. Intergroup guideline for management of childhood ITP and evaluation of the guideline. Rinsho Ketsueki. 2004;45:428-35.
12. Shirahata A, Ishii E, Eguchi H, Okawa H, Ohta S, Kaneko T, et al. Consensus guideline for diagnosis and treatment of childhood idiopathic thrombocytopenic purpura. Int J Hematol. 2006;83:29-38. (Pubitemid 43172739)
13. Treutiger I, Rajantie J, Zeller B, Elinder G, Rosthöj S, NOPHO ITP Working Group. Initial management of children with newly diagnosed idiopathic thrombocytopenic purpura in the Nordic countries. Acta Paediatr. 2006;95:726-31. (Pubitemid 43879568)
14. Imbach P, Kühne T, Müller D, Berchtold W, Zimmerman S, Elalfy M, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the International Childhood ITP Study Group (ICIS). Pediatr Blood Cancer. 2006;46:351-6. (Pubitemid 43201852)
15. Ahmed I, Rajpurkar M, Thomas R, Chitlur M. Initial lymphocyte count and the development of persistent/chronic immune thrombocytopenic purpura. Pediatr Blood Cancer. 2010;55:508-11.
16. Kato S, Tachikawa T, Ozawa K, Konno M, Okuda M, Fujisawa T, et al. Urine-based enzyme-linked immunosorbent assay for the detection of Helicobacter pylori Infection in children. Pediatrics. 2001;107:E87.
17. Okuda M, Fukuda Y. Helicobacter pylori infection in childhood. Nihon Rinsho. 2009;67:2239-44.
18. Donato H, Picón A, Martinez M, Rapetti MC, Rosso A, Gomez S, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer. 2009;52:491-6.
19. ElAlfy M, Farid S, Abdel Maksoud A. Predictors of chronic idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 2010;54:959-62.
20. Ho WL, Lee CC, Chen CJ, Lu MY, Hu FC, Jou ST, et al. Clinical features, prognostic factors, and their relationship with antiplatelet antibodies in children with immune thrombocytopenia. J Pediatr Hematol Oncol. 2012;34:6-12.
21. Watts RG. Idiopathic thrombocytopenic purpura: a 10-year natural history study at the children hospital of Alabama. Clin Pediatr (Phila). 2004;43:691-702. (Pubitemid 39363387)
22. Glanz J, France E, Xu S, Hayes T, Hambidge S. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatirics. 2008;121:e506-12.
23. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura; current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4-13.
24. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168-86.